ADIS characterized cytotoxic lymphocytes in peripheral blood as potential markers for predicting AD and investigated the impact of sleep disturbances on these markers.
NEURONET's aim was to set up a platform to boost synergy & collaboration across the Innovative Medicines Initiative projects of the Neurodegenerative Disorders portfolio,
The PRIME project aimed to understand insulin-related multimorbidity across the lifespan, uncover its underlying mechanisms, and develop tools for early diagnosis, better care, and prevention.
RECOGNISED applied innovative approaches to identify the molecular mechanisms involved in the high prevalence of cognitive impairment and dementia in the T2D population.